Vedere Bio Funding & Investors
Cambridge, MA
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.
vederebio.comTotal Amount Raised: $98,000,000
Vedere Bio Funding Rounds
Series A
$77,000,000
Series A Investors
Octagon Capital AdvisorsMission BioCapitalSamsara BioCapitalAtlas VentureCasdin CapitalRD FundSeries A
$21,000,000
Series A Investors
Atlas VentureMission BioCapitalFoundation Fighting Blindness
Funding info provided by Diffbot.